



# Advanced Therapy Medicinal Products: from the Revolution to the Evolution of cell-based drugs

**Maria Luisa Nolli**



*Webinar for members of EIPG  
in conjunction with PIER and  
University College Cork*

*[Click here to  
register](#)*

*Tuesday 3<sup>rd</sup> October 2023 at 17.00 CEST (16.00 BST)*

## About the Speaker

Maria Luisa Nolli is co-founder and CEO of NCNbio, a company focused on Industrial Technology Transfer in biotechnology. She was the founder and former CEO of Areta International and was the site manager for the company from 2000 to 2012. Maria Luisa is also a co-founder of two university spin offs. She brought to all these companies her experience in cell biology and immunology, matured as a scientist and team leader in the multinational companies of Dow Chemical as Dow Lepetit, Merrell Dow, Marion Merrell Dow and Hoechst Marion Roussel. She received her doctoral degree in Biological Sciences from the University of Pavia and was a doctoral fellow in Brussels, Pavia and Naples. She is a Board Member of several Associations, including AFI, has won prizes for innovation and is a member of the Patent Commission of the University of Milano. She is a professor and is author or co-author of more than 60 publications and 11 patents.

## Overview of Webinar

Advanced Therapy Medicinal Products (ATMPs) are at the frontier of new medicine. The revolution is in the nature of these drugs and in their groundbreaking new opportunities for the treatment of disease. The manufacture involves a new generation of bioreactors, both modular and single-use for dedicated batches and appropriate for the treatment of a single patient. Together with the incredible opportunities of ATMPs, there are challenges that must be addressed such as their cost-benefit, sustainability by national health systems and access to a greater number of patients.

## Learning Outcomes

At the end of this webinar you will be able to:

- Define the current revolution in medicine and understand the definition and description of ATMPs
- Compare the differences between synthetic small molecules and monoclonal antibodies
- Outline the development process of an ATMP, be aware of the case histories of ATMPs on the market (CART Kymriah, Yescarta, Genic Therapy Luxturna), understand the revolution of ATMPs manufacturing and their future manufacture
- Be informed about the regulations driving the steps in the development of ATMPs
- Recognise the concept of sustainability of these drugs by the NHS and the concept of access to patients
- Appreciate the evolution of ATMPs is in curing not only haematological diseases but also solid tumours.

## To Join the Webinar

Please register by filling out the [Registration Form](#). Keep a record of the streaming details of the event that will be **shown on your screen at the time of your registration**.

## Continuing Education

A certificate of attendance will be issued after the webinar. The session will be an hour of Continuing Education.